Please login to the form below

Not currently logged in
Email:
Password:

ozanimod

This page shows the latest ozanimod news and features for those working in and with pharma, biotech and healthcare.

Novartis builds its case for novel MS treatment ofatumumab

Novartis builds its case for novel MS treatment ofatumumab

That competition paves the way for new entries, including Novartis’ ofatumumab and Bristol-Myers Squibb’s oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod which is also currently under review with

Latest news

More from news
Approximately 3 fully matching, plus 20 partially matching documents found.

Latest Intelligence

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    The FDA accepted the filing for Ozanimod in June 2019 with a target PDUFA date of 25 March 2020. ... As with ozanimod, if OMB-157 is approved it will find a very crowded multiple sclerosis market with some very notable competitors, particularly in the

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    treatment ozanimod and myelodysplastic syndromes/beta thalassaemia candidate luspatercept – to deliver on their potential.

  • Pharma deals in July 2015 Pharma deals in July 2015

    Celgene believes Receptos's ozanimod in phase III for ulcerative colitis could reach peak sales of $4bn to $6bn per year. ... Receptos / Celgene. Company acquisition. Ozanimod in Phase 3 for auto-immune disease.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...
InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much
Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...

Infographics